CRISPR

Partner Content

Partner Content

Commercialization of novel gene-editing technology in beta-t...

Gene therapies and research into them have grown immensely in recent years, offering more novel tools in regenerative medicine to fight disease, including rare diseases and genetic disorders.

R&D

CRISPR therapies targeting the next breakthrough in oncology

The potential of CRISPR technology has been a hot topic in the industry ever since it was first developed, but as trials progress further into the clinic, what therapeutic areas could be se

News

Bayer trumpets $1bn CRISPR deal with Mammoth Bio

Bayer has bolstered its cell and gene therapy platform by securing access to a CRISPR-based gene-editing platform developed by US biotech Mammoth Biosciences.

R&D

Pharma’s use of synthetic biology could deliver radical inno...

Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways of treating disease and accelerating drug development, says Debiopharm's Tanja Dowe.

News

Nobel winner Charpentier's CRISPR Therapeutics gets $900m in...

CRISPR Therapeutics is to receive a hefty $900m payment from Vertex after the companies amended a collaboration to develop, manufacture and market a gene editing therapy for sickle cell dis

Views & Analysis

Casting aside CRISPR scissors and making a point with base e...

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology and next-generati